Skip to content

Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery

Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery: Randomized Controlled Trial on Postoperatory Oppioid Consumption

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05558917
Acronym
ESPECS
Enrollment
160
Registered
2022-09-28
Start date
2022-09-07
Completion date
2023-11-07
Last updated
2022-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Carcinoma, Breast Neoplasms

Keywords

PECS2, ESP BLOCK, Breast Anesthesia, Mastectomy, Breast Cancer

Brief summary

The study aims to compare the efficacy of the two operating blocks PECS2 and ESP by measuring postoperative opioid consumption and, secondarily, to compare (between PECS and ESP) postoperative opioid consumption between surgery with/without axillary cavity dissection and with/without implantation of prosthesis or expansion

Detailed description

Breast cancer is the most frequent type of cancer in the female population. Early detection is the most effective tool for improving prognosis, and the surgical approach plays a central role in the treatment of this disease. However, many are the psychophysical implications that patients face: among the main ones is postoperative and chronic pain, a symptom that greatly worsens the quality of life. In the last decade it has been witnessed an important development of locoregional anesthesia techniques in all surgeries. In breast surgery, particularly mastectomy, the following locoregional anesthesia techniques are referred to as the Gold Standard: 1. PVB (Paravertebral Block) 2. PECS2 BLOCK (or modified PECS). For the same purposes, ESP Block (Erector Spinae Plane Block) has been applied experimentally, which has already shown its effectiveness in breast surgery in several trials. By comparing postoperative opioid consumption between the two groups of patients, divided into PECS Block and ESP Block, the study aims to identify which anesthesia block is most effective in order to improve the care of patients undergoing mastectomy.

Interventions

PROCEDUREPECS BLOCK 2

With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.

PROCEDUREESP BLOCK

Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.

Sponsors

Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing mastectomy exclusively for breast cancer * Presence of written informed consent to the trial

Exclusion criteria

* Bilateral breast surgery * Previous drug use * Chronic opioid and minor opioid therapy * BMI \>40 * Allergy or contraindications to taking Paracetamol and Toradol * Inability to use PCA (Patient Controlled Analgesia) * Intraoperative opioid administration * Patients with neuropathy

Design outcomes

Primary

MeasureTime frameDescription
Morphine equivalent consumption in the postoperative 24h in simple mastectomiesPostoperative 24 hoursMorphine-equivalent consumption in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in simple mastectomies.

Secondary

MeasureTime frameDescription
Morphine-equivalent consumption in the postoperative 24h in mastectomies with prosthesis or expander placementPostoperative 24 hoursConsumption of morphine equivalents in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in astecctomies with prosthesis or expander placement.
Morphine-equivalent consumption in the postoperative 24h in mastectomies with axillary cavity emptying and implantation of prosthesis or expanderPostoperative 24 hoursConsumption of morphine equivalents in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in mastectomies with axillary cavity emptying and implantation of prosthesis or expander
PONV (Post Operating Nausea and Vomiting)Immediately after the surgery and at 2-4-8-12-24 hours after surgeryNumber of times the patient experienced nausea or vomiting
Complications incidencePostoperative 24 hoursNumber of times the patient experienced complications such as bleeding or pneumothorax
Morphine-equivalent consumption in the postoperative 24h in mastectomies with axillary cavity emptyingPostoperative 24 hoursMorphine-equivalent consumption in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in mastectomies with axillary cavity emptying.
Length of hospitalizationUp to 7 daysLenght in days
Patient's Likert ScalePostoperative 24 hoursPatient satisfaction, from 1 - Strongly disagree to 5 - Strongly agree
Surgeon's Likert scalePostoperative 24 hoursSurgeon satisfaction, from 1 - Strongly disagree to 5 - Strongly agree
Time from end of surgery to first walkPostoperative 72 hoursTime in hours

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026